EMERYVILLE, Calif.,
Aug. 16, 2021 /PRNewswire/
-- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic
biotechnology company active in the Clean Health and Beauty markets
through its consumer brands, and a top supplier of sustainable and
natural ingredients, announced today that it will be hosting an
encore to its first three-part virtual investor mini-series themed
"Delivering on the Promise of Synthetic Biology".
The first three webinars in Amyris' investor series focused on
the power of Amyris' proprietary Lab-to-MarketTM
biotechnology platform, its clean beauty consumer brands, and its
ingredients pipeline. The goal is to continue to engage and educate
current and prospective investors about Amyris' busines model and
the power of its platform.
Amyris will host its fourth webinar titled Lab-to-Market,
Delivering Disruptive Health and Beauty Products on
Tuesday September 28, 2021 at
1:00pm ET (10:00 am PT). The session will include a
presentation regarding Amyris' differentiated cannabigerol ("CBG")
ingredient and its product formulation that clears the skin and
reduces bone inflammation and other body pains for topical
application, followed by a live Q&A. Webcast details will be
published closer to the date of the webinar.
Amyris plans to hold a fifth and sixth session in the series
focused on its advantaged portfolio before the end of 2021.
"We have received very positive feedback on our virtual investor
mini-series and have decided to continue with this successful
format to inform and educate our stakeholders," commented
John Melo, President and Chief
Executive Officer. "We are executing very well on our Lab-to-Market
capability to create, manufacture and sell differentiated
ingredients and disruptive consumer products which are at the core
of our winning business model. We are experiencing strong demand
for our ingredients and are accelerating growth with our consumer
brands in the third quarter. We are launching three new brands this
month for which we are already experiencing very strong retail
interest. We expect a strong second half from the combination of
these new brands and accelerated growth from our existing
ingredients portfolio and consumer brands."
About Amyris
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris is proud to own
and operate a family of consumer brands - all built around its No
Compromise® promise of clean ingredients: Biossance® clean beauty
skincare, Pipette® clean baby skincare, and Purecane™, a
zero-calorie sweetener naturally derived from sugarcane. For more
information, please visit http://www.amyris.com.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and
Purecane are trademarks or registered trademarks of Amyris, Inc. in
the U.S. and/or other countries.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding future events, such as Amyris'
expectations regarding demand for its ingredients, third quarter
consumer growth, timing and prospects regarding the launch of three
new brands, and strong financial performance in the second half of
the year resulting from new brands and accelerated growth of its
existing products. These statements are based on management's
current expectations and actual results and future events may
differ materially due to risks and uncertainties, including risks
related to Amyris' liquidity and ability to fund operating and
capital expenses, risks related to its financing activities, risks
related to potential delays or failures in completing and
integrating planned acquisitions, risks related to potential delays
or failures in development, regulatory approval, launch, production
and commercialization of products, risks related to Amyris'
reliance on third parties, and other risks detailed from time to
time in filings Amyris makes with the Securities and Exchange
Commission, including Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. Amyris
disclaims any obligation to update information contained in these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-launches-next-virtual-investor-mini-series-301355726.html
SOURCE Amyris, Inc.